A trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis
Project management at the University of Würzburg:
BDNF is a potent survival factor for lesioned and degenerating motoneurons in the various animal models for human disease. We could show in a first phase 1/2 clinical study that intrathecal infusion of BDNF is well tolerated, and that BDNF is taken up by degenerating motoneurons and activates signalling pathways in these cells.
Projekt period: from 01.1999 to 12.2000
DFG ( To 61/8-3 ) ,Granting date: 19.08.1996
Wirtschaftsunternehmen ( Amgen )
8420135 DFG To 61/8-1